Lecithin-modified superoxide dismutase(Lecithin-modified superoxide dismutase) - 药物靶点：SOD1_在研适应症：慢性肾病，特发性肺纤维化，脑梗塞_专利_临床

概要

基本信息

药物类型

酶

别名

PC-SOD、PC-SOD NE、PCSOD

+ [5]

靶点

SOD1

作用机制

SOD1调节剂(超氧化物歧化酶调节剂)

治疗领域

神经系统疾病心血管疾病呼吸系统疾病+ [2]

在研适应症

慢性肾病特发性肺纤维化脑梗塞+ [4]

非在研适应症-

原研机构

LTT Bio-Pharma Co., Ltd.

在研机构

LTT Bio-Pharma Co., Ltd.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Lecithin-modified superoxide dismutase 相关的临床试验

JPRN-UMIN000009573 / Completed

PC-SOD NE (PhaseIIa) -Repeated Dose Study in IPF patients- - PC-SOD NE (PhaseIIa)

开始日期2011-05-31

申办/合作机构

LTT Bio-Pharma Co., Ltd.

JPRN-UMIN000008921 / Completed

PC-SOD NE (Phase I) -Repeated Dose Study in healthy volunteers- - PC-SOD NE (Phase I)

开始日期2010-12-21

申办/合作机构

LTT Bio-Pharma Co., Ltd.

JPRN-UMIN000008920 / Completed临床1期

PC-SOD NE(Phase I) -Single Dose Study in healthy volunteers- - PC-SOD NE(Phase I)

开始日期2010-09-22

申办/合作机构

LTT Bio-Pharma Co., Ltd.

100 项与 Lecithin-modified superoxide dismutase 相关的临床结果

登录后查看更多信息

100 项与 Lecithin-modified superoxide dismutase 相关的转化医学

登录后查看更多信息

100 项与 Lecithin-modified superoxide dismutase 相关的专利（医药）

登录后查看更多信息

32

项与 Lecithin-modified superoxide dismutase 相关的文献（医药）

2023-12-31·Drug Delivery

A quality by design approach for the synthesis of palmitoyl-L-carnitine-loaded nanoemulsions as drug delivery systems

Article

作者: Arroyo-Urea, E. M. ; Muñoz-Hernando, María ; González-Paredes, Ana ; Leo-Barriga, Marta ; Herranz, Fernando

Nanoemulsions (NE) are lipid nanocarriers that can efficiently load hydrophobic active compounds, like palmitoyl-L-carnitine (pC), used here as model molecule. The use of design of experiments (DoE) approach is a useful tool to develop NEs with optimized properties, requiring less experiments compared to trial-and-error approach. In this work, NE were prepared by the solvent injection technique and DoE using a two-level fractional factorial design (FFD) as model was implemented for designing pC-loaded NE. NEs were fully characterized by a combination of techniques, studying its stability, scalability, pC entrapment and loading capacity and biodistribution, which was studied ex-vivo after injection of fluorescent NEs in mice. We selected the optimal composition for NE, named pC-NE_U, after analysis of four variables using DoE. pC-NE_U incorporated pC in a very efficient manner, with high entrapment efficiency (EE) and loading capacity. pC-NE_U did not change its initial colloidal properties stored at 4 °C in water during 120 days, nor in buffers with different pH values (5.3 and 7.4) during 30 days. Moreover, the scalability process did not affect NE properties and stability profile. Finally, biodistribution study showed that pC-NE_U formulation was predominantly concentrated in the liver, with minimal accumulation in spleen, stomach, and kidneys.

2022-01-01·Life Sciences3区 · 医学

Novel pharmacological effects of lecithinized superoxide dismutase on ischemia/reperfusion injury in the kidneys of mice

3区 · 医学

Article

作者: Shimoda, Mikako ; Kawahara, Masahiro ; Mizushima, Tohru ; Takafuji, Ayaka ; Kubota, Maho ; Tanaka, Ken-Ichiro

Renal ischemia/reperfusion (I/R) injury is a major clinical problem because it can cause acute kidney injury (AKI) or lead to the transition from AKI to chronic kidney disease (CKD). Oxidative stress, which involves the production of reactive oxygen species (ROS), plays an important role in the development and exacerbation of I/R-induced kidney injury. However, we have previously reported that lecithinized superoxide dismutase (PC-SOD), a SOD derivative with high tissue affinity and high stability in plasma, has beneficial effects in various disease models because of its inhibitory effect on ROS production. Therefore, we aimed to determine the effects of intravenous PC-SOD administration in a mouse model of renal injury induced by I/R. PC-SOD markedly ameliorated the I/R-induced increases in markers of renal damage (urea nitrogen, creatinine, neutrophil gelatinase-associated lipocalin, and interleukin-6) and tubular necrosis 48 h after the intervention. We also found that PC-SOD significantly ameliorated the I/R-induced increase in ROS production, using an ex vivo imaging system. Furthermore, PC-SOD inhibited the increases in expression of markers of fibrosis (α-smooth muscle actin and collagen 1A1) 96 h after, and renal fibrosis 25 days after I/R was induced. Finally, we found that PC-SOD ameliorated the I/R-induced AKI in mice with high-fat diet-induced prediabetes. These results suggest that PC-SOD inhibits AKI and the transition from AKI to CKD through the inhibition of ROS production. Therefore, we believe that PC-SOD may represent an effective therapeutic agent for I/R-induced renal injury.

2017-02-01·American Journal of Respiratory Cell and Molecular Biology1区 · 医学

Evaluation of Lecithinized Superoxide Dismutase for the Prevention of Acute Respiratory Distress Syndrome in Animal Models

1区 · 医学

Article

作者: Kuba, Keiji ; Kawahara, Masahiro ; Imai, Yumiko ; Mizushima, Tohru ; Tanaka, Ken-ichiro ; Tamura, Fumiya ; Sugizaki, Toshifumi

For acute respiratory distress syndrome (ARDS), mechanical ventilation (MV) is a life-saving intervention without alternative; however, MV can cause ventilator-induced lung injury. Reactive oxygen species (ROS) play important roles in the pathogenesis of both ARDS and ventilator-induced lung injury. Lecithinized superoxide dismutase (PC-SOD) overcomes the limitations of superoxide dismutase such as low tissue affinity and low stability in plasma. In this study, we examined the effect of PC-SOD on tissue injury, edema, and inflammation in the lung and other organs of mice subjected to cecal ligation and puncture (CLP), LPS administration, or MV. The severity of the lung injury was assessed on the basis of vascular permeability, histopathologic evaluation, and lung mechanics. Intravenous PC-SOD administration (the first administered just before CLP) increased the survival rate and decreased vascular permeability in mice subjected to CLP. PC-SOD, but not dexamethasone or sivelestat sodium hydrate (sivelestat), suppressed CLP-induced kidney injury and systemic inflammation. PC-SOD also suppressed vascular permeability, tissue injury, and inflammation in the lung induced by LPS administration. Moreover, PC-SOD, but not dexamethasone or sivelestat, suppressed vascular permeability, edema, tissue injury, and mechanical alterations in the lung induced by MV. In vivo imaging analysis of ROS revealed that CLP, LPS administration, and MV increased the level of ROS and that this increase was suppressed by PC-SOD. The results of this study thus suggest that, on the basis of its ROS-reducing properties, intravenous administration of PC-SOD may be beneficial for patients at high risk of developing ARDS.

100 项与 Lecithin-modified superoxide dismutase 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	日本	LTT Bio-Pharma Co., Ltd.	2022-01-30
特发性肺纤维化	临床2期	日本	LTT Bio-Pharma Co., Ltd.	2022-01-30
脑梗塞	临床2期	日本	LTT Bio-Pharma Co., Ltd.	-
心肌梗塞	临床2期	日本	LTT Bio-Pharma Co., Ltd.	-
周围神经系统疾病	临床2期	日本	LTT Bio-Pharma Co., Ltd.	-
慢性阻塞性肺疾病	临床1期	日本	LTT Bio-Pharma Co., Ltd.	2022-01-30
急性呼吸窘迫综合征	临床1期	日本	LTT Bio-Pharma Co., Ltd.	-